VERACYTE REPORTS ASSET ACQUISITION & UNREGISTERED EQUITY SALE

TL;DR

**VCYT just completed an asset deal involving unregistered equity sales, watch for impact on financials.**

AI Summary

Veracyte, Inc. (VCYT) filed an 8-K on February 6, 2024, reporting an event that occurred on February 5, 2024, related to the completion of an acquisition or disposition of assets and unregistered sales of equity securities. This filing indicates a significant corporate action, likely involving the exchange of equity for assets, which could impact the company's financial structure and future growth prospects. Investors should note this as it signals a strategic move that could alter the company's asset base and potentially dilute existing shareholders if new shares were issued.

Why It Matters

This filing signals a strategic shift for Veracyte, potentially expanding its operations or divesting non-core assets, which could affect its long-term value and shareholder equity.

Risk Assessment

Risk Level: medium — The filing mentions both an acquisition/disposition and unregistered equity sales, which can introduce financial and dilution risks if not managed effectively.

Analyst Insight

Investors should monitor Veracyte's upcoming financial disclosures for details on the acquired/disposed assets and the specifics of the unregistered equity sales to assess the long-term impact on valuation and potential dilution.

Key Numbers

• $0.001 — Par value per share (The par value of Veracyte's Common Stock, indicating the nominal value of each share.)

Key Players & Entities

• VERACYTE, INC. (company) — the registrant filing the 8-K
• February 5, 2024 (date) — date of the earliest event reported
• February 6, 2024 (date) — date the 8-K was filed
• VCYT (company) — trading symbol for Veracyte, Inc.
• The Nasdaq Stock Market LLC (company) — exchange where Veracyte's Common Stock is registered
• $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Veracyte's next quarterly earnings report will likely include details about the financial impact of this acquisition/disposition and equity sale. (Veracyte, Inc.) — high confidence, target: Q1 2024 Earnings Report
• The unregistered sales of equity securities may lead to a slight dilution of existing shareholder value. (Veracyte, Inc. shareholders) — medium confidence, target: Ongoing

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share VCYT The Nasdaq Stock Market
• $70.0 million — C2i Genomics"), for a purchase price of $70.0 million to C2i Genomics securityholders, subjec
• $8.0 million — he Merger Agreement, Veracyte deposited $8.0 million of the Closing Consideration into escro
• $0.2 million — of the C2i Genomics securityholders and $0.2 million of the Closing Consideration was deposi
• $25.0 million — to the Closing Consideration, of up to $25.0 million based on the achievement of future perf

Filing Documents

• vcyt-20240205.htm (8-K) — 29KB
• 0001384101-24-000004.txt ( ) — 156KB
• vcyt-20240205.xsd (EX-101.SCH) — 2KB
• vcyt-20240205_lab.xml (EX-101.LAB) — 25KB
• vcyt-20240205_pre.xml (EX-101.PRE) — 13KB
• vcyt-20240205_htm.xml (XML) — 3KB

01. Completion of Acquisition or Disposition of Assets

Item 2.01. Completion of Acquisition or Disposition of Assets. On February 5, 2024 (the "Closing Date"), Veracyte, Inc., a Delaware corporation ("Veracyte"), completed its previously announced acquisition of C2i Genomics, Inc., a Delaware corporation ("C2i Genomics"), for a purchase price of $70.0 million to C2i Genomics securityholders, subject to customary purchase price adjustments (the "Closing Consideration"), pursuant to an Agreement and Plan of Merger, dated as of January 5, 2024, by and among Veracyte, C2i Genomics, Canary Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Veracyte, Veracyte Diagnostics, LLC, a Delaware limited liability company and a wholly owned subsidiary of Veracyte, and Fortis Advisors LLC, as the securityholders' agent (the "Securityholders' Agent") (such agreement, the "Merger Agreement" with such acquisition pursuant to the Merger Agreement being referred to herein as the "Acquisition"). Under the Merger Agreement, Veracyte deposited $8.0 million of the Closing Consideration into escrow to secure certain indemnification obligations of the C2i Genomics securityholders and $0.2 million of the Closing Consideration was deposited with the Securityholders' Agent for payment or reimbursement of certain expenses potentially to be incurred by the Securityholders' Agent in connection with the Acquisition. The as-adjusted remainder of the Closing Consideration will be paid to the C2i Genomics securityholders in an aggregate amount of up to 2,698,349 shares of Veracyte common stock (such shares of common stock, the "Stock Consideration"), and in the case of any C2i Genomics securityholder who did not certify they were an "accredited investor" (as such term is defined in Rule 501(a) under the Securities Act of 1933, as amended (the "Securities Act")), cash in lieu of their respective portion of Stock Consideration. The exact number of shares to be issued by Veracyte to C2i Genomics securityholders as Stock Consideratio

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information set forth above under Item 2.01 relating to the Stock Consideration is hereby incorporated by reference into this Item 3.02. Such Stock Consideration will be deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 5, 2024 VERACYTE, INC. By: /s/ Rebecca Chambers Name: Rebecca Chambers Title: Chief Financial Officer Principal Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR